Shares of Onconova Therapeutics Inc. (NASDAQ:ONTX) traded down 13.5% on Monday . The company traded as low as $3.96 and last traded at $3.98, with a volume of 56,096 shares traded. The stock had previously closed at $4.60.

A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Onconova Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a report on Friday, April 1st. HC Wainwright reaffirmed a “buy” rating on shares of Onconova Therapeutics in a report on Tuesday, March 29th.

The company’s market capitalization is $10.82 million. The stock has a 50-day moving average price of $5.33 and a 200-day moving average price of $5.15.

Onconova Therapeutics (NASDAQ:ONTX) last issued its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. On average, equities analysts anticipate that Onconova Therapeutics Inc. will post ($7.40) earnings per share for the current year.

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases, cellular metabolism or cell division.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.